Quantcast

Industry news that matters to you.  Learn more

Archives for June 2011

ApoCell Launches Revolutionary Circulating Cancer Cell Detection System

ApoCell, Inc. announced earlier this week that it has completed the first prototype to commercialize a revolutionary technology that improves the detection of more types of cancer cells circulating in the blood, including rare cell types that have previously gone undetected. Invented by scientists at The University of Texas MD Anderson Cancer Center’s Laboratory of Diagnostic Microsystems and exclusively licensed to ApoCell, a leader in biomarker analysis, the technology also enables the capture of circulating tumor cells (CTCs) in a live and viable state, enabling post-detection testing and culturing.

Cleveland Clinic Selected as Site for Michael J. Fox Foundation Parkinson’s Disease Study

Cleveland Clinic has been selected as a site for the Parkinson’s Progression Markers Initiative (PPMI), a landmark five-year research study that aims to identify biomarkers of the disease. The study is sponsored by the Michael J. Fox Foundation.

Immunodepletion Followed by LC-MS/MS is Best for Serum-based Clinical Discovery Biomarkers

The discovery of human serum or plasma biomarkers is hindered by the presence of highly abundant proteins that may mask many low abundant species that have clinical value. A recent study in the journal Proteomics systematically compared immunodepletion of 6, 14 or 20 proteins using serum from renal transplant patients and analyzed reproducibility, depth of coverage, efficiency and specificity on two analytical platforms: 2-D differential gel electrophoresis (DIGE) (‘top-down’) and liquid chromatography tandem mass spectrometry (LC-MS/MS) (‘bottom-up’).